Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00484354 · ClinicalTrials.gov registry record · Phase 2
Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT00484354 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 123 participants.
The verdict
NCT00484354, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the incidence of acute renal failure (ARF) in high risk patients who undergo coronary artery bypass grafting (CABG) is reduced by treating patients in the perioperative period with intravenous (IV) sodium bicarbonate. Patients will be randomized in a 50:50 allocation to receive either IV sodium bicarbonate or IV normal saline. The volume of fluid given in each arm of the study is equal. All other interventions in those patients will be according to standard cardiothoracic anesthesia protocol at our institution.
Interventions
- OTHER Placebo
- DRUG Sodium bicarbonate
- OTHER Normal saline
- OTHER Bicarbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2006-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00484354
The ClinicalTrials.gov registry entry for NCT00484354 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00484354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00484354 about?
NCT00484354 is a clinical study titled "Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery". The purpose of this study is to determine if the incidence of acute renal failure (ARF) in high risk patients who undergo coronary artery bypass grafting (CABG) is reduced by treating patients in the perioperative period with intravenous (IV) sodium bicarbonate. Patients will be randomized in a 50:5...
What is the current status of trial NCT00484354?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2006-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00484354?
The interventions under investigation include: Placebo (OTHER), Sodium bicarbonate (DRUG), Normal saline (OTHER), Bicarbonate (OTHER).
Who is sponsoring clinical trial NCT00484354?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.